The Drug Approval Process
In this short webinar, James Radke provides an overview of the drug approval process in Canada: Health Canada, CADTH, PMPRB, INESSS, pCPA, and the proposed National Pharmacare program.
Read More
Tag: PMPRB
Zeal Tips
Pharma Investing Less in Canadian Research
The Patented Medicine Prices Review Board (PMPRB) published their 2017 report on August 22, noting $16.8 billion in patented medicines sold in Canada in 2017.
Read More
The Drug Review Process in Canada
Anyone who has participated in the Canadian healthcare system understands that it is complicated. And like many endeavours, the more government agencies involved, the more complicated (and convoluted) it seems to get. The same is true for the approval and disbursement of new medicines.
Read More
Rare Disease Day in Canada
Rare Disease Day is the day that countries raise awareness of the 1 in 12 people who have a rare condition. Here in Canada, advocacy groups will be asking the community to understand that while each rare disease represents a small population, as a whole the 7000+ rare diseases account for about 8% of the population.
Read More
Innovative Medicines Canada vs Ottawa
On Feb 9, 2018, Pamela C. Fralick, President of Innovative Medicines Canada gave a presentation at Economic Club of Canada in Toronto. The premise of her talk is that the new drug review process being proposed by PMPRB will hurt patients and R & D investment.
Read More
When Gene Therapy Undergoes Review by Health Canada – Will The Experts Be Ready?
Spark Therapeutics’ FDA approved gene therapy, Luxturna, has a price tag – $850,000 (U.S.). Or $425,00 per eye for a rare type of blindness. The therapy is approved for persons with confirmed biallelic RPE65 mutation-associated retinal dystrophy.
Read More
Zeal Access Editorial: Why is Canada 13th?
This week, Health Canada and the Patented Medicine Prices Review Board (PMPRB) hosted a webinar outlining their proposed changes to the Patented Medicines Regulations. Under the new proposals, the pricing of drugs will be compared to their prices in 12 other countries so that Canadians will pay a price for the drug that is comparable to other countries.
Read More
Patented Medicine Prices Review Board (PMPRB) Changing How It Reviews Drugs?
Patented Medicine Prices Review Board (PMPRB) published its initial thoughts on how to operationalize the Minister of Health’s proposed amendments to the Patented Medicines Regulations, (Published on December 2, 2017).
Read More
